Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Thomas Mika; Katharina Strate; Swetlana Ladigan; Clemens Aigner; Uwe Schlegel; Iris Tischoff; Sabine Tischer-Zimmermann; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Roland Schroers

doi:10.3389/fmed.2019.00295

Frontiers in Medicine (Dec 2019)

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Thomas Mika,
Katharina Strate,
Swetlana Ladigan,
Clemens Aigner,
Uwe Schlegel,
Iris Tischoff,
Sabine Tischer-Zimmermann,
Britta Eiz-Vesper,
Britta Maecker-Kolhoff,
Roland Schroers

Affiliations

Thomas Mika: Department of Medicine, Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany
Katharina Strate: Department of Medicine, Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany
Swetlana Ladigan: Department of Medicine, Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany
Clemens Aigner: Department of Thoracic Surgery, Ruhrlandklinik, University Hospital Essen, Essen, Germany
Uwe Schlegel: Department of Neurology, Ruhr-University Bochum, Bochum, Germany
Iris Tischoff: Department of Pathology, Ruhr-University Bochum, Bochum, Germany
Sabine Tischer-Zimmermann: Institute for Transfusion Medicine, Hannover Medical School, Hanover, Germany
Britta Eiz-Vesper: Institute for Transfusion Medicine, Hannover Medical School, Hanover, Germany
Britta Maecker-Kolhoff: Department of Pediatric Hematology and Oncology, Hannover Medical School, Hanover, Germany
Roland Schroers: Department of Medicine, Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany

DOI: https://doi.org/10.3389/fmed.2019.00295
Journal volume & issue: Vol. 6

Abstract

Read online

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords